← Back to screener

Mirum Pharmaceuticals, Inc. MIRM

Rank #2484 · Nasdaq · $5.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
14.4
P/E
-31.7
P/B
36.49
ROE
-115.1%
Op. Margin
-58.6%
Debt Ratio
313%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -31.7x, P/B 36.49x. Ranks in the top 83% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -115.1%. Ranks in the top 91% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 313%. Ranks in the top 72% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 141.8% year over year. Ranks in the top 3% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019–$-0.1B$-0.1B$0.0B––
2020–$-0.1B$-0.1B$-0.0B–-95
2021$0.0B$-0.1B$-0.1B$0.1B–53
2022$0.0B$-0.2B$-0.1B$0.2B-906.1101
2023$0.0B$-0.2B$-0.1B$0.2B-906.1123
2024$0.1B$-0.1B$-0.1B$0.1B-170.3331
2025$0.2B$-0.1B$-0.2B$0.1B-58.6313

← See the full screener